Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol

Achieving adequate immunosuppression for lung transplant recipients in the first year after lung transplantation is a key challenge. Prophylaxis of allograft rejection must be balanced with the adverse events associated with immunosuppressive drugs, for example infection, renal failure, and diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuurmans, Macé M., Raeber, Miro E., Roeder, Maurice, Hage, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054078/
https://www.ncbi.nlm.nih.gov/pubmed/36984489
http://dx.doi.org/10.3390/medicina59030488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054078/
https://www.ncbi.nlm.nih.gov/pubmed/36984489
http://dx.doi.org/10.3390/medicina59030488

Ejemplares similares